These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30670300)

  • 1. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.
    Ledov VA; Golovina ME; Markina AA; Knirel YA; L'vov VL; Kovalchuk AL; Aparin PG
    Vaccine; 2019 Feb; 37(8):1062-1072. PubMed ID: 30670300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outer Membrane Vesicles Derived from
    Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
    Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
    Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW
    EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV; Roberts F; Verma NK
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
    Citiulo F; Necchi F; Mancini F; Rossi O; Aruta MG; Gasperini G; Alfini R; Rondini S; Micoli F; Rappuoli R; Saul A; Martin LB
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009826. PubMed ID: 34644291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.
    Lin J; Smith MA; Benjamin WH; Kaminski RW; Wenzel H; Nahm MH
    Clin Vaccine Immunol; 2016 Aug; 23(8):681-8. PubMed ID: 27280622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.
    Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB
    Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 17. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
    J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
    PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R
    Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
    Passwell JH; Ashkenazi S; Banet-Levi Y; Ramon-Saraf R; Farzam N; Lerner-Geva L; Even-Nir H; Yerushalmi B; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Vaccine; 2010 Mar; 28(10):2231-2235. PubMed ID: 20056180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.